MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine

Qin,Ye; Liu,Xiu-Jun; Li,Liang; Liu,Xu-Jie; Li,Yi; Gao,Rui‑Juan; Shao,Rong-Guang; Zhen,Yong-Su

doi:10.3892/or.2014.3169

MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine

Authors:
- Ye Qin
- Xiu-Jun Liu
- Liang Li
- Xu-Jie Liu
- Yi Li
- Rui‑Juan Gao
- Rong-Guang Shao
- Yong-Su Zhen
View Affiliations

Affiliations: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China
Published online on: May 7, 2014 https://doi.org/10.3892/or.2014.3169
Pages: 121-130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To increase the antitumor efficacy, in the present study, we proposed several settings of matrix metalloproteinase (MMP)-2/9-oriented combinations that comprise the MMP-2/9-targeting fusion protein dFv-LDP and the MMP inhibitor doxycycline (DOX) in association with EGFR/HER2-bispecific fusion protein Ec-LDP-Hr, its enediyne-energized analogue Ec-LDP-Hr-AE, and gemcitabine (GEM). The expressions of various fusion proteins were detected by western blot analysis. Proliferation and migration inhibition of cells were determined by MTT and Transwell assay, respectively. The binding capability of dFv-LDP and Ec-LDP-Hr to cancer cells was examined by ELISA, cell immunofluorescence coimmunoprecipitation and confocal assays. Animal experiments were set to investigate the antitumor efficacy of various combinations against colorectal carcinoma HCT-15 xenograft in athymic mice. These two targeting proteins dFv-LDP and Ec-LDP-Hr had strong binding capabilities and antiproliferation effects on various cancer cell lines. Enhanced therapeutic efficacy in vivo was observed in the MMP-2/9-targeting fusion protein dFv-LDP integrated combinations including: i) dFv-LDP and Ec-LDP-Hr, ii) dFv-LDP and enediyne-energized fusion protein Ec-LDP-Hr-AE, iii) dFv-LDP and Ec-LDP-Hr-AE plus DOX, and iv) dFv-LDP and GEM plus DOX against colorectal cancer HCT-15 xenograft in athymic mice. In setting iii, DOX (20 mg/kg), dFv-LDP (20 mg/kg) and Ec-LDP-Hr-AE (0.3 mg/kg) alone suppressed tumor growth by 35, 49.7 and 67.5%, respectively. The combination of dFv-LDP and Ec-LDP-Hr-AE was 75.1%. Furthermore, this combination plus DOX showed stronger efficacy with an inhibitory rate of 82.7%. In setting iv, the combination of dFv-LDP and GEM suppressed tumor growth by 66.3%. Notably, the tumor inhibitory rate of the dFv-LDP/GEM/DOX combination reached 85.5%, producing initial shrinkage after the first administration. The MMP-2/9-oriented combination strategy that employs the MMP-2/9-targeting antibody-based fusion protein and the small molecular inhibitor DOX as the basic composed agents may enhance antitumor efficacy in association with the EGFR/HER2-targeting fusion protein and GEM. This multiple targeting approach may be useful for enhancing antitumor efficacy against colorectal cancer.

View Figures

View References

1	Sapra P and Shor B: Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 138:452–469. 2013. View Article : Google Scholar : PubMed/NCBI
2	Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS and Kragh M: Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 70:588–597. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sapra P, Damelin M, Dijoseph J, et al: Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther. 12:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
4	Maron R1, Schechter B, Mancini M, Mahlknecht G, Yarden Y and Sela M: Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA. 110:15389–15394. 2013. View Article : Google Scholar : PubMed/NCBI
5	McCaffery I, Tudor Y, Deng H, et al: Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 19:4282–4289. 2013. View Article : Google Scholar : PubMed/NCBI
6	Shankaran V, Obel J and Benson AD III: Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist. 15:157–167. 2010. View Article : Google Scholar : PubMed/NCBI
7	Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hynes NE and Lane HA: ERBB receptors and cancer: the complexicity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
9	Harrison S and Benziger H: The molecular biology of colorectal carcinoma and its implications: a review. Surgeon. 9:200–210. 2011. View Article : Google Scholar : PubMed/NCBI
10	Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A and Smith RC: Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol. 29:1125–1134. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 13:565–569. 1993.PubMed/NCBI
12	Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
13	Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.
14	Cho YB, Lee WY, Song SY, Shin HJ, Yun SH and Chun HK: Matrix metalloproteinase-9 activity is associated with poor prognosis in T3–T4 node-negative colorectal cancer. Hum Pathol. 38:1603–1610. 2007.PubMed/NCBI
15	Hong SW, Kang YK, Lee B, et al: Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol. 27:133–139. 2011. View Article : Google Scholar : PubMed/NCBI
16	Guo XF, Zhu XF, Shang Y, Zhang SH and Zhen YS: A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res. 16:2085–2094. 2010. View Article : Google Scholar
17	Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q and Zhen Y: A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice. Cancer Lett. 295:124–133. 2010. View Article : Google Scholar
18	Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN and Strimpakos AS: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer Res. 31:2971–2974. 2011.PubMed/NCBI
19	Pelosof L, Yerram SR, Ahujia N, Delmas A, Danilova L, Herman JG and Azad NS: CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer. 134:596–605. 2014. View Article : Google Scholar
20	Shen LC, Chen YK, Lin LM and Shaw SY: Anti-invasion and anti-tumor growth effect of doxycycline treatment for human oral squamous-cell carcinoma - in vitro and in vivo studies. Oral Oncol. 46:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
21	Guimaraes DA, Rizzi E, Ceron CS, et al: Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol. 108:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
22	Son K, Fujioka S, Iida T, et al: Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells. Anticancer Res. 29:3995–4004. 2009.PubMed/NCBI
23	Heinemann V, Douillard JY, Ducreux M and Peeters M: Targeted therapy in metastatic colorectal cancer - an example of personalized medicine in action. Cancer Treat Rev. 39:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
24	Grünwald V and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 95:851–867. 2003.PubMed/NCBI
25	Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
26	Winder T and Lenz HJ: Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology. 138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
27	Medinger M and Drevs J: Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des. 11:1139–1149. 2005. View Article : Google Scholar : PubMed/NCBI
28	Coussens LM and Werb Z: Matrix metalloproteinases and the development of cancer. Chem Biol. 3:895–904. 1996. View Article : Google Scholar : PubMed/NCBI
29	Matsuyama Y, Takao S and Aikou T: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol. 80:105–110. 2002. View Article : Google Scholar
30	Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N and Talieri M: Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol. 22:383–389. 2001. View Article : Google Scholar : PubMed/NCBI
31	Hilska M, Roberts PJ, Collan YU, et al: Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 121:714–723. 2007. View Article : Google Scholar : PubMed/NCBI
32	Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E and Mirtsou-Fidani V: Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis. 17:158–168. 1997.PubMed/NCBI
33	Roeb E, Dietrich CG, Winograd R, et al: Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9. Cancer. 92:2680–2691. 2001. View Article : Google Scholar : PubMed/NCBI
34	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
35	Garden OJ, Rees M, Poston GJ, et al: Guidelines for resection of colorectal cancer liver metastases. Gut. 55(Suppl 3): iii1–iii8. 2006. View Article : Google Scholar : PubMed/NCBI
36	Gesto DS1, Cerqueira NM, Fernandes PA and Ramos MJ: Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem. 19:1076–1087. 2012. View Article : Google Scholar : PubMed/NCBI